IRVINE, Calif. - Eledon Pharmaceuticals Inc. (NASDAQ: ELDN) has announced a medical milestone with the successful completion of a kidney xenotransplantation at Massachusetts General Hospital.
The procedure involved the transplantation of a kidney from a genetically altered pig into a 62-year-old man suffering from end-stage kidney disease and was performed on Monday, marking a significant advancement in the field of organ transplantation.
Tegoprubart, Eledon's investigational anti-CD40L antibody, played a key role in the immunosuppressive treatment regimen, helping to prevent the patient's body from rejecting the transplanted organ. The use of tegoprubart in this context is part of the company's broader efforts to provide new options for patients in need of organ transplants amid a global shortage of available organs.
The recent xenotransplantation follows Eledon's involvement in both kidney and heart transplant procedures using tegoprubart, which has been observed to be safe and well-tolerated in multiple studies. The company is also conducting preclinical studies and two global clinical trials focused on the prevention of organ rejection in kidney transplant recipients.
In a recent Phase 1b study involving 11 participants, tegoprubart was reported to be generally safe and well-tolerated, effectively preventing rejection and allowing for post-transplant kidney function above historical averages. The Phase 2 BESTOW study, which compares tegoprubart with tacrolimus, a current standard treatment for rejection prevention, is currently recruiting participants and aims to complete enrollment by the end of 2024.
This development is based on a press release statement from Eledon Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.